Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | ANPEP | P15144 | 1/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15826790 | 1.00 | GLA (0.55) | GLAALDH1A1KDM4EHSD17B10ANPEP | |
| Hydrochloric Acid SCHEMBL7341620 | 0.98 | GLA (0.58) | GLAALDH1A1KDM4EHSD17B10ANPEP | |
| SCHEMBL21994880 | 0.89 | GAA (0.54) | GLAALDH1A1KDM4EHSD17B10ANPEP | |
| SCHEMBL21952349 | 0.89 | GAA (0.54) | GLAALDH1A1KDM4EHSD17B10ANPEP | |
| SCHEMBL15326764 | 0.87 | GSR (0.50) | ALDH1A1KMT2AGRM5GRM2 | |
| SCHEMBL2179400 | 0.86 | KDM4E (0.52) | GLAALDH1A1KDM4EHSD17B10ANPEP | |
| SCHEMBL24063106 | 0.83 | DPP7 (0.50) | ALDH1A1SMN1; SMN2MAPTKMT2AGRM5 | |
| SCHEMBL20683320 | 0.83 | DPP7 (0.50) | ALDH1A1SMN1; SMN2MAPTKMT2AGRM5 | |
| SCHEMBL2088089 | 0.83 | DPP7 (0.50) | ALDH1A1SMN1; SMN2MAPTKMT2AGRM5 | |
| SCHEMBL25662147 | 0.83 | GSR (0.46) | ALDH1A1SMN1; SMN2KMT2AGRM5GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118256591-A | Cyclic peptide compound having high membrane permeability and library comprising same | 中外制药株式会社 | 2024-06-28 | — | — | CN | disclosed |
| CN-110869544-B | Cyclic peptide compound having high membrane permeability and library comprising same | 中外制药株式会社 | 2024-03-08 | — | — | CN | disclosed |
| WO-2023244554-A1 | CYCLIC PEPTIDES FOR TRAPPING INTERLEUKIN-1 BETA | MERCK SHARP & DOHME LLC (US) | 2023-12-21 | — | — | WO | disclosed |
| US-20200131669-A1 | CYCLIC PEPTIDE COMPOUND HAVING HIGH MEMBRANE PERMEABILITY, AND LIBRARY CONTAINING SAME | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2020-04-30 | — | — | US | disclosed |
| EP-3636807-A1 | CYCLIC PEPTIDE COMPOUND HAVING HIGH MEMBRANE PERMEABILITY, AND LIBRARY CONTAINING SAME | Chugai Seiyaku Kabushiki Kaisha (JP) | 2020-04-15 | — | — | EP | disclosed |
| CN-110869544-A | Cyclic peptide compound having high membrane permeability and library containing same | 中外制药株式会社 | 2020-03-06 | — | — | CN | disclosed |
| EP-2480247-B1 | NOVEL NPR-B AGONISTS | SHIRE ORPHAN THERAPIES GMBH (DE) | 2020-02-12 | — | — | EP | disclosed |
| EP-2480247-B1 | NOVEL NPR-B AGONISTS | SHIRE ORPHAN THERAPIES GMBH (DE) | 2020-02-12 | — | — | EP | disclosed |
| US-10196423-B2 | NPR-B agonists | SHIRE ORPHAN THERAPIES GMBH (DE) | 2019-02-05 | — | — | US | disclosed |
| US-10196423-B2 | NPR-B agonists | SHIRE ORPHAN THERAPIES GMBH (DE) | 2019-02-05 | — | — | US | disclosed |
| WO-2011075471-A2 | NOVEL NPR-B AGONISTS AND METHODS OF USE FOR THE TREATMENT OF C-TYPE NATRIURETIC PEPTIDE-MEDIATED DISORDERS | ALCON RESEARCH, LTD. (US) | 2011-06-23 | — | — | WO | disclosed |
| US-20110112038-A1 | NOVEL NPR-B AGONISTS | ALCON RESEARCH, LTD. (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110112038-A1 | NOVEL NPR-B AGONISTS | ALCON RESEARCH, LTD. (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110112038-A1 | NOVEL NPR-B AGONISTS | ALCON RESEARCH, LTD. (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110077381-A1 | NOVEL NPR-B AGONISTS | ALCON RESEARCH, LTD. (US) | 2011-03-31 | — | — | US | disclosed |
| US-20110077381-A1 | NOVEL NPR-B AGONISTS | ALCON RESEARCH, LTD. (US) | 2011-03-31 | — | — | US | disclosed |
| WO-2011038061-A2 | NOVEL NPR-B AGONISTS | ALCON RESEARCH, LTD. (US) | 2011-03-31 | — | — | WO | disclosed |
| WO-2011038066-A2 | NOVEL NPR-B AGONISTS | ALCON RESEARCH, LTD. (US) | 2011-03-31 | — | — | WO | disclosed |
| EP-0832110-A1 | ANTIVIRAL PEPTOID COMPOUNDS | Novartis AG (CH) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996040759-A1 | ANTIVIRAL PEPTOID COMPOUNDS | NOVARTIS AG (CH) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077381-A1 | NOVEL NPR-B AGONISTS | NPR1, NPR3, NPBWR1 | GLA 4509/4885ALDH1A1 4515/4885KDM4E 3095/4885 |
| US-10196423-B2 | NPR-B agonists | NPR1, NPR3, NPBWR1 | GLA 4446/4885ALDH1A1 4620/4885KDM4E 3389/4885 |
| US-20200131669-A1 | CYCLIC PEPTIDE COMPOUND HAVING HIGH MEMBRANE PERMEABILITY, AND LIBRARY CONTAINING SAME | VIP, SLC7A1, TRPV1 | GLA 4693/4885ALDH1A1 4817/4885KDM4E 4113/4885 |
| US-20110112038-A1 | NOVEL NPR-B AGONISTS | NPR1, NPR3, NPBWR1 | GLA 4509/4885ALDH1A1 4515/4885KDM4E 3095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.